Correspondence 0001683168-26-004266 from CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc.
Date: May 22, 2026 · CIK: 0001729427 · Accession: 0001683168-26-004266
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296033
Letter
CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
May 22, 2026
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Re: CNS Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-296033
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the "Company"), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 P.M. (Eastern Time) on May 26, 2026, or as soon thereafter as possible on such date.
Very truly yours,
CNS Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 May 22, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-296033 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the "Company"), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 P.M. (Eastern Time) on May 26, 2026, or as soon thereafter as possible on such date. Very truly yours, CNS Pharmaceuticals, Inc. By: /s/ Steve O'Loughlin Name: Steve O'Loughlin Title: Chief Financial Officer